Chimeric Therapeutics is trading 8% down at A$0.04, extending a steady decline from A$0.05 over recent sessions amid light news flow and investor profit-taking.
- The move appears driven by continued investor caution toward the microcap biotech rather than any fresh fundamental changes to its cell therapy pipeline.
- No new company announcements, clinical updates, or sector-wide biotech news have been reported to trigger the recent price action.